Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 10, 2016

M&As this week: Sichuan Kelun Pharma, CiToxLAB

Sichuan Kelun Pharma has announced its intention to acquire stakes in two pharmaceutical companies, one based in Guangxi and another in Changshu.

Sichuan Kelun Pharma has announced its intention to acquire stakes in two pharmaceutical companies, one based in Guangxi and another in Changshu.

"It will acquire the remaining 20% stake in the Guangxi-based company for $5.3m to obtain 100% ownership, and 35% in the Changshu-based biopharmaceutical company."

It will acquire the remaining 20% stake in the Guangxi-based company for $5.3m to obtain 100% ownership, and 35% in the Changshu-based biopharmaceutical company.

French pre-clinical services provider CiToxLAB Group has completed the acquisition of Canadian company, AccelLAB, with the aim of strengthening its position in the non-clinical contract research market and extending its services portfolio to medical devices.

The target company is a pre-clinical contract research organisation that employs approximately 100 people.

CiToxLab operates in France, Canada, Hungary and Denmark with a total of 1,000 staff as a result of the acquisition.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU